American Oriental Bioengineering, Inc. (AOBI)
OTCMKTS · Delayed Price · Currency is USD
0.0130
+0.0118 (983.33%)
At close: Aug 13, 2026
AOBI Revenue
American Oriental Bioengineering had revenue of $17.94M in the quarter ending September 30, 2013, a decrease of -34.65%. This brings the company's revenue in the last twelve months to $121.58M, down -10.20% year-over-year. In the year 2012, American Oriental Bioengineering had annual revenue of $145.10M, down -31.78%.
Revenue (ttm)
121.58M
Revenue Growth
-10.20%
P/S Ratio
0.00
Revenue / Employee
32.69K
Employees
3,719
Market Cap
949.00
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2012 | 145.10M | -67.59M | -31.78% |
| Dec 31, 2011 | 212.69M | -93.25M | -30.48% |
| Dec 31, 2010 | 305.94M | 9.79M | 3.31% |
| Dec 31, 2009 | 296.15M | 31.51M | 11.91% |
| Dec 31, 2008 | 264.64M | 104.16M | 64.90% |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GlobeImmune | 6.21M |
| Alzex Neuropharma | 4.73M |
| DNAPrint Genomics | 1.93M |
| Trevena | 546.00K |
| Proteonomix | 26.00K |